⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 26, 2009Clinical Cancer Research

Longitudinal Cytokine Expression during IMRT for Prostate Cancer and Acute Treatment Toxicity

Eva Christensen Melania Pintilie Kenneth Evans Michelle Lenarduzzi Cynthia Ménard Charles Catton Eleftherios P. Diamandis Robert G. Bristow

View at Publisher

Ask AI

Bookmark

Share

Abstract

Determination of radiation-response signatures is feasible using multiplexed immunoassays and is a promising predictive early biomarker of toxicity outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Christensen et al. (2009) studied this question.

synapsesocial.com/papers/69d97686a1d151c65f6843f1 https://doi.org/10.1158/1078-0432.ccr-09-0245

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Serial circulating tumour DNA monitoring in first-line advanced NSCLC (COPE): a randomized, two-arm non-comparative phase II trialClinical Cancer Research · Wed,
2DuoBody®-FAPαxDR4 is a novel DR4 agonist that induces potent antitumor activity through FAPα-dependent, DR4-transactivation-mediated apoptosisClinical Cancer Research · Wed,
3Carboplatin Plus Mirvetuximab Soravtansine In Platinum-Sensitive Ovarian Cancer: A Phase 2 Nonrandomized Clinical TrialClinical Cancer Research · Wed,
4Long-Term Outcomes and Biomarker Correlates of a Multi-Institutional Phase II Study of Hypofractionated Proton Beam Therapy for Unresectable Primary Liver TumorsClinical Cancer Research · Wed,
5HexaBody-OX40 promotes antitumor immunity through FcγR crosslinking-independent OX40 agonist activity and enhances effects of PD-1 blocking antibodiesClinical Cancer Research · Wed,

More from Clinical Cancer Research

Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicenter, single-arm, phase II trialFri,
Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumorsThu,
Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registryWed,
DNA-Based Biomarkers as Predictors of Carboplatin Response in Neoadjuvant Treatment for Hormone Receptor Positive and Triple-Negative Breast CancerWed,
Multi-institutional study evaluating the role of liquid biopsy to determine risk of extraocular disease, therapy response and recurrence in retinoblastomaWed,